These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 13180761)

  • 1. Studies in human subjects on active immunization against poliomyelitis. II. A practical means for inducing and maintaining antibody formation.
    SALK JE; BAZELEY PL; BENNETT BL; KRECH U; LEWIS LJ; WARD EN; YOUNGNER JS
    Am J Public Health Nations Health; 1954 Aug; 44(8):994-1009. PubMed ID: 13180761
    [No Abstract]   [Full Text] [Related]  

  • 2. [Examinations on poliomyelitis antibodies in the population and the practical significance of antibody determination in poliomyelitis vaccination].
    KELLER W
    Monatsschr Kinderheilkd (1902); 1956 Mar; 104(3):135-6. PubMed ID: 13321825
    [No Abstract]   [Full Text] [Related]  

  • 3. [The formation of neutralizing antibodies in humans after poliomyelitis immunization with the Behring vaccine].
    KELLER W; SAUTHOFF R
    Dtsch Med Wochenschr; 1955 Sep; 80(37):1329-31. PubMed ID: 13261706
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antibody response of infants to a "booster" dose of the Salk type of poliomyelitis vaccine given from 5 to 6 months after early primary immunization].
    MORRONE G; NUNZIATA B
    Pediatria (Napoli); 1961; 69():851-6. PubMed ID: 14476315
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunization of infants with living attenuated poliomyelitis virus; laboratory investigations of alimentary infection and antibody response in infants under six months of age with congenitally acquired antibodies.
    FLACK A; HUMMELER K; HUNT AD; JERVIS GA; KOPROWSKI H; NORTON TW; STOKES J
    J Am Med Assoc; 1956 Dec; 162(14):1281-8. PubMed ID: 13366742
    [No Abstract]   [Full Text] [Related]  

  • 6. A method for the rapid determination of immunogenic potency of poliomyelitis vaccines by single vaccination of white rats.
    GHENDON IZ; MARCHENKO AT
    Acta Virol; 1959 Oct; 3():250-2. PubMed ID: 13849934
    [No Abstract]   [Full Text] [Related]  

  • 7. [Virus excretion and antibody formation after double oral poliomyelitis vaccination (Cox triple vaccine and Sabin vaccine)].
    JUST M; BUERGIN-WOLFF A
    Ann Paediatr; 1962; 199():245-9. PubMed ID: 14452877
    [No Abstract]   [Full Text] [Related]  

  • 8. The antibody response to poliomyelitis vaccine in school-children at the time of initial vaccination and one year later.
    ARMSTRONG CW; MOSS GW; POTTER FC
    Can J Public Health; 1957 Mar; 48(3):96-100. PubMed ID: 13413743
    [No Abstract]   [Full Text] [Related]  

  • 9. The relationship between specific skin reaction and neutralizing antibody titers in the young infant following immunization with poliomyelitis (Salk-type) vaccine.
    MORRONE G; NUNZIATA B
    Ann Paediatr; 1961; 196():389-98. PubMed ID: 13772899
    [No Abstract]   [Full Text] [Related]  

  • 10. Observations on the complement-fixing antibody response in human poliomyelitis. Influence of age and vaccination status.
    LENNETTE EH; MAGOFFIN RL; SCHMIDT NJ
    J Immunol; 1962 Sep; 89():358-66. PubMed ID: 14464002
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity, in children, of ultraviolet-treated poliomyelitis vaccine.
    WOLF AM; SHAUGHNESSY HJ; CHURCH RE; MILZER A; JANOTA M; OPPENHEIMER F; MORRISSEY RA; NAFTULIN H; CHAPMAN JW; LEVINSON SO
    J Am Med Assoc; 1956 Jun; 161(9):775-81. PubMed ID: 13319005
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunization of chimpanzees and human beings with avirulent strains of poliomyelitis virus.
    SABIN AB
    Ann N Y Acad Sci; 1955 Sep; 61(4):1050-6. PubMed ID: 13340614
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of guinea pigs in tests for immunogenic capacity of poliomyelitis virus preparations.
    GARD S; WESSLEN T; FAGRAEUS A; SVEDMYR A; OLIN G
    Arch Gesamte Virusforsch; 1956; 6(5):401-11. PubMed ID: 13340710
    [No Abstract]   [Full Text] [Related]  

  • 14. Complement-fixing antigens of living and inactivated poliovirus. II. Complement-fixing activity of poliomyelitis vaccine and its relation to immunogenic potency.
    WARREN J; HARE JD; GOLDMAN C
    Am J Public Health Nations Health; 1959 Jan; 49(1):53-61. PubMed ID: 13617534
    [No Abstract]   [Full Text] [Related]  

  • 15. [Study of poliomyelitis antibodies in Lorraine before, during and after vaccination with the Lepine vaccine in a group of subjects observed systematically].
    de LAVERGNE ; GERBAUT P; LORRAIN J; POLJE F; GILGENKRANTZ ; LE MOYNE MT; MATHIEU J
    Ann Inst Pasteur (Paris); 1959 Dec; 97():848-54. PubMed ID: 14414644
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunization of man against poliomyelitis with attenuated preparations of living virus.
    KOPROWSKI H
    Ann N Y Acad Sci; 1955 Sep; 61(4):1039-49. PubMed ID: 13340613
    [No Abstract]   [Full Text] [Related]  

  • 17. Poliovirus antibody response after various vaccination schedules and at different ages.
    MACLEOD DR; ARMSTRONG CW; MOSS GW; POTTER FC; WILSON RJ
    Can Med Assoc J; 1959 Sep; 81(6):443-9. PubMed ID: 14419587
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibody responses to British poliomyelitis vaccine of children with naturally occurring antibody.
    RUSSELL K
    Br Med J; 1958 Mar; 1(5071):622-4. PubMed ID: 13510748
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination against poliomyelitis with live virus vaccines. 5. Neutralizing antibody levels one year after vaccination.
    DANE DS; DICK GW; BRIGGS M; NELSON R
    Br Med J; 1958 Nov; 2(5106):1187-8. PubMed ID: 13584893
    [No Abstract]   [Full Text] [Related]  

  • 20. [Poliomyelitis antibody development in adults after vaccination with Lederle triple vaccine of Sabin strains].
    GSELL O; WIESMANN E
    Schweiz Med Wochenschr; 1962 Apr; 92():475-6. PubMed ID: 13902511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.